CSL (ASX:CSL) chairman Professor John Shine used his AGM address to announce a $950m share buyback and detail the company's achievements over the past 12 months. [ + ]

Recognised as this year's distinguished Lemberg Medalist at the ComBio2014 meeting, Professor Marilyn Anderson reflects on a research career that began with organic chemistry and moved through oncogenes and cloning technology to settle in plant biology, and continues to span basic research to commercialisation. [ + ]

While there is absolutely no scientific evidence that crystals can be used to predict the future or provide protection or healing, they play a critical role in establishing the structure of matter.

The current Ebola crisis has demonstrated that 'inadvertent' contamination is very hard to eradicate and can have deadly consequences. [ + ]

For the first time, researchers have been able to open a kind of window into the inner workings of a lithium-ion battery. Using a neutron beam, the researchers were able to track the flow of lithium atoms into and out of an electrode in real time as a battery charged and discharged.

All five HCV genotype 3 patients completing treatment during a pilot trial of BIT225 with IFN/RBV had undetectable virus levels 12 weeks post-treatment. [ + ]

When it comes to finding new sources of energy, the Australian Plasma Fusion Research Facility (APFRF) is looking onwards and upwards - quite literally, in fact.

The sciences are producing huge amounts of data and it is humanly impossible to keep up with this ever-growing body of scientific material. How can researchers deal with this volume of information?

Regeneus (ASX:RGS) has given its side of the story over a 7:30 report airing concerns regarding the company's Hi-Q-Cell stem cell therapy and its use by injured AFL players. [ + ]

With the potential to transform medical research, the Medical Research Future Fund needs the science community to get behind it. [ + ]

Phosphagenics' TPM-Tretinoin drug candidate outperformed the market leader during a phase II trial, with the results suggesting that TPM itself has inherent anti-acne qualities. [ + ]

Prima BioMed (ASX:PRR) has proposed to buy immuno-oncology company Immutep, in what chair Lucy Turnbull considers to be the most significant move in the company's history. [ + ]

A new technique for monitoring BK viral loads in kidney transplant patients offers the potential to improve patient outcomes and reduce clinical load. [ + ]

Germany's Merck has arranged to acquire chemical and biochemical supplier Sigma-Aldrich in a deal worth US$17bn. [ + ]

​Australian and South Korean researchers have developed a method to help reduce biomedical and prosthetic device failure rates - currently sitting at 17% - by enabling Braille-like communication between medical implants and a patient's cells. [ + ]